MRVI Stock: Price, Earnings History and SEC Filings
Maravai LifeSciences Holdings, Inc. (MRVI) last traded at $7.81, down 7.68% on the latest session and up 2.0% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.07 against an analyst estimate of $-0.07, a beat of 0.0%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
MRVI earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 6, 2026 | $-0.07 | $-0.07 | +0.00% |
| Mar 2026 | May 7, 2026 | $-0.03 | $-0.07 | +57.14% |
| Dec 2025 | Feb 25, 2026 | $-0.07 | $-0.09 | +22.22% |
| Sep 2025 | Nov 6, 2025 | $-0.14 | $-0.08 | -75.00% |
MRVI beat the analyst EPS estimate in 2 of its last 4 reported quarters. Source: Nasdaq.
How MRVI reacts to earnings
Across its last 8 earnings releases, MRVI moved 11.8% on average the next session, in either direction. It rose after 3 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-06 | After close | -0.32% |
| 2026-05-07 | After close | +23.10% |
| 2026-02-25 | After close | +9.20% |
| 2025-11-06 | After close | -0.69% |
| 2025-08-11 | After close | +30.58% |
| 2025-05-12 | After close | -2.83% |
| 2025-03-18 | After close | -5.81% |
| 2025-02-24 | After close | -21.70% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
MRVI financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $186M | -$131M | -$71M | -70.4% | $-0.90 |
| 2024 | $259M | -$145M | -$22M | -55.9% | $-1.05 |
| 2023 | $289M | -$119M | $61M | -41.2% | $-0.90 |
| 2022 | $883M | $220M | $519M | 24.9% | $1.67 |
| 2021 | $799M | $182M | $354M | 22.8% | $1.56 |
| 2020 | $284M | $89M | $127M | 31.3% | $2.36 |
| 2019 | $143M | -$4M | $7M | -3.1% | $-0.03 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for MRVI
- 10-Q · Aug 7, 2026
- 8-K · Aug 6, 2026Results of operations, Financial statements and exhibits
- 8-K · Jun 3, 2026Material agreement, Agreement terminated, New financial obligation
- 8-K · May 29, 2026Shareholder vote
- 10-Q · May 8, 2026
- 8-K · May 7, 2026Results of operations, Financial statements and exhibits
- DEF 14A · Apr 24, 2026
- 10-K · Feb 26, 2026
- 8-K · Feb 25, 2026Results of operations, Financial statements and exhibits
- 10-Q · Nov 7, 2025
Insider filing activity
MRVI insiders filed 5 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
MRVI news
- Maravai LifeSciences Announces November 2026 Investor Conference ScheduleOct 29, 2026 · finance.yahoo.com
- Is Maravai LifeSciences Holdings (MRVI) Priced Too Highly For Its Sales?Oct 27, 2026 · finance.yahoo.com
About Maravai LifeSciences Holdings, Inc.
Maravai LifeSciences Holdings, Inc. (MRVI) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.